How to manage hypotension in a patient undergoing hemodialysis who is not on any antihypertensive medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Hypotension in Hemodialysis Patients Not on Antihypertensives

In hemodialysis patients experiencing hypotension who are not on antihypertensive medications, immediately stop or reduce ultrafiltration, administer IV normal saline (100-250 mL bolus), place in Trendelenburg position, and provide supplemental oxygen, then systematically modify the dialysis prescription by keeping ultrafiltration rates below 6 mL/h/kg through extended treatment time (minimum 4 hours) or increased frequency (three times weekly), while reassessing the estimated dry weight upward as it is likely set too low. 1, 2, 3

Immediate Acute Interventions

When hypotension occurs during dialysis, execute these steps in rapid sequence:

  • Stop or reduce ultrafiltration immediately to prevent further blood pressure decline and allow vascular refilling—this is the single most critical intervention 1, 2, 3
  • Administer intravenous normal saline bolus of 100-250 mL to rapidly expand plasma volume, though avoid routine saline administration for every episode as this perpetuates volume overload and fails to address the underlying problem 1, 3
  • Place patient in Trendelenburg position (head down, legs elevated) to improve venous return and increase blood pressure 1, 2
  • Provide supplemental oxygen to improve tissue oxygenation and reduce symptoms 1, 2

Critical Dialysis Prescription Modifications

The most common cause of hypotension in dialysis patients not on antihypertensives is excessive ultrafiltration rate relative to vascular refilling capacity:

  • Keep ultrafiltration rates below 6 mL/h/kg as rates exceeding this threshold are associated with higher mortality risk and increased hypotension 1, 3
  • Extend treatment time to minimum 4 hours per session to slow the ultrafiltration rate and allow adequate vascular refilling 1, 3
  • Increase dialysis frequency from twice to three times weekly when patients have excessive interdialytic weight gain requiring aggressive ultrafiltration that exceeds vascular refilling capacity 1, 3

Common pitfall: Continuing twice-weekly dialysis forces dangerously high ultrafiltration rates (often exceeding 10-13 mL/h/kg) and inadequate solute clearance—this must be avoided 3

Reassess Estimated Dry Weight

In patients not on antihypertensives, hypotension strongly suggests the target dry weight is set too low:

  • Gradually probe the dry weight upward over 4-12 weeks without inducing hypotension, as the current target is likely underestimating true dry weight 3
  • Look for signs of improving nutrition (increasing serum albumin, creatinine, or normalized protein catabolic rate) alongside hypotension, which indicates the dry weight needs upward adjustment 1
  • Consider residual urine output as this commonly leads to underestimation of true dry weight—a frequent pitfall in these patients 1, 3

Dialysate Modifications

Modify the dialysate composition to enhance hemodynamic stability:

  • Increase dialysate sodium concentration to 148 mEq/L, especially early in the dialysis session, or implement sodium profiling (starting higher at 148 mEq/L and gradually decreasing) to maintain vascular stability 1, 2
  • Reduce dialysate temperature from 37°C to 34-35°C to increase peripheral vasoconstriction and cardiac output through increased sympathetic tone, which decreases symptomatic hypotension from 44% to 34% 1, 2
  • Switch from acetate-containing to bicarbonate-containing dialysate to prevent inappropriate decreases in total vascular resistance and venous pooling 1, 2, 3

Caution: Increased dialysate sodium may lead to increased thirst, interdialytic weight gain, and subsequent hypertension; reduced dialysate temperature may cause uncomfortable hypothermia in some patients 2

Pharmacological Management with Midodrine

For patients with persistent hypotension despite dialysis prescription modifications:

  • Administer midodrine (oral α1-adrenergic agonist) 30 minutes before dialysis initiation at a mean dose of 8 mg (range 2.5-25 mg) to increase peripheral vascular resistance and enhance venous return 1, 2, 4
  • Midodrine significantly increases minimal systolic pressure from 93 mmHg to 107 mmHg during hemodialysis and post-dialysis pressures from 116/62 to 130/68 mmHg 5
  • Monitor for supine hypertension as midodrine can cause elevated blood pressure when lying flat; patients should avoid taking their last daily dose within 3-4 hours of bedtime 4
  • Note that midodrine is removed by dialysis, so timing of administration is critical 4

Contraindications and precautions: Use midodrine cautiously in patients with urinary retention, diabetes, visual problems, renal impairment (start at 2.5 mg), or hepatic impairment; avoid concomitant use with MAO inhibitors, and monitor carefully when used with cardiac glycosides or beta-blockers 4

Long-Term Prevention Strategies

Implement these measures to prevent recurrent hypotension:

  • Limit sodium intake to <5.8 g/day to reduce thirst and interdialytic weight gain, as water intake adjusts to match salt intake 1, 3
  • Restrict interdialytic weight gain to <3% of body weight between sessions to prevent excessive ultrafiltration requirements 1, 3
  • Avoid food intake immediately before or during hemodialysis, as this causes decreased peripheral vascular resistance and may precipitate hypotension 1, 2
  • Maintain hemoglobin at 11 g/dL per NKF-K/DOQI guidelines to improve oxygen-carrying capacity and cardiovascular compensation during ultrafiltration 1, 3

Special Consideration: Chronically Hypotensive Patients

For patients with persistent hypotension despite all interventions:

  • Consider transition to peritoneal dialysis as these patients may tolerate continuous ambulatory peritoneal dialysis (CAPD) better than hemodialysis due to slower, continuous ultrafiltration 6, 3

Algorithm for Management

Step 1: During acute hypotensive episode → Stop/reduce UF + IV saline + Trendelenburg + O2 1, 2

Step 2: Reassess dry weight upward (likely too low) 1, 3

Step 3: Modify dialysis prescription → UF rate <6 mL/h/kg via longer sessions (≥4 hours) or increased frequency (3x/week) 1, 3

Step 4: Adjust dialysate → Increase sodium to 148 mEq/L + Reduce temperature to 34-35°C + Switch to bicarbonate 1, 2

Step 5: If hypotension persists → Add midodrine 30 minutes pre-dialysis (start 2.5-8 mg) 1, 2, 5

Step 6: Implement prevention → Sodium restriction <5.8 g/day + Interdialytic weight gain <3% + Avoid pre-dialysis meals + Maintain Hgb 11 g/dL 1, 3

Step 7: If refractory → Consider peritoneal dialysis 6, 3

References

Guideline

Management of Hypotension in Hemodialysis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hypotension During Hemodialysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Intradialytic Hypotension Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Can blood pressure medications and vitamins be given to a patient before dialysis?
What antihypertensive medication can be ordered as needed for a patient with hypertension undergoing dialysis?
What are the recommended antihypertensives for patients undergoing hemodialysis?
Which antihypertensive medication, Amlodipine, Clonidine, Atenolol, or Telmisartan, is most likely being dialyzed and cleared during Hemodialysis (HD)?
How to manage a hemodialysis patient with heart failure and hypotension symptoms?
Can congenital or acquired nevi, such as port-wine stains or spider nevi, be considered in the differential diagnosis of a patient presenting with reddish-brown, telangiectatic macules and patches, associated with flushing, itching, and burning?
What is the role of Hemoglobin A1c (HbA1c) in assessing anesthesia risk in patients with diabetes or those at risk of developing diabetes?
What is the recommended approach to managing a patient with asthma?
Can a vasculitic nevus (vascular inflammatory nevus) present with reddish-brown, telangiectatic macules and patches, associated with flushing, itching, and burning?
What is the role of acetazolamide in managing idiopathic intracranial hypertension (IIH) in patients with a ventriculoperitoneal (VP) shunt?
What is the best management approach for an 87-year-old female with acute coronary syndrome (ACS) and community-acquired pneumonia (CAP), presenting with shortness of breath, new onset fever, 3rd degree AV block, lateral wall ischemia, and compensated respiratory acidosis, on medications including omeprazole (Prilosec) 40mg daily, enoxaparin (Lovenox) 0.4cc every 12 hours, clopidogrel (Plavix) 75mg daily, aspirin 80mg daily, ceftazidime (Fortaz) 1g every 8 hours, levofloxacin (Levaquin) 500mg daily, and N-acetylcysteine (NAC) 600mg daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.